Lyso-thermosensitive liposomal doxorubicin: A novel approach to enhance efficacy of thermal ablation of liver cancer

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 2, 2009, Pages 333-343

  Poon, Ronnie T P ^a   Borys, Nicholas ^b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Celsion Corp   (United States)

Author keywords

Hepatocellular carcinoma; Lyso thermosensitive liposomal doxorubicin; Radiofrequency ablation

Indexed keywords

1 STEAROYL 2 HYDROXY SN GLYCERO 3 PHOSPHOCHOLINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE N METHOXYPOLYETHYLENEGLYCOL 2000; ACETIC ACID; ALCOHOL; ALPHA2B INTERFERON; CISPLATIN; DIPALMITOYLPHOSPHATIDYLCHOLINE; DOXORUBICIN; FLUOROURACIL; LIPOSOME; NOLATREXED; THERMODOX; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; LYSOPHOSPHATIDYLCHOLINE;

ABDOMINAL PAIN; ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BACKACHE; BLADDER SPASM; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER THERAPY; CLINICAL TRIAL; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXCRETION; DRUG FEVER; DRUG FORMULATION; DRUG METABOLISM; DYSGEUSIA; DYSPNEA; FATIGUE; GRANULOCYTOPENIA; HEART EJECTION FRACTION; HEAT SENSITIVITY; HEMATURIA; HEPATOBILIARY DISEASE; HUMAN; HYPERBILIRUBINEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERTENSION; HYPERTHERMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOTENSION; INSOMNIA; LARYNX PAIN; LEG EDEMA; LETHARGY; LEUKOCYTE COUNT; LEUKOPENIA; LIMB PAIN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER TOXICITY; LYMPHOCYTOPENIA; MOOD DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PATIENT CODING; PROSTATE CANCER; RADIOFREQUENCY ABLATION; REVIEW; SIDE EFFECT; SORE THROAT; STOMATITIS; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; TUMOR VOLUME; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION; VOMITING; WEIGHT REDUCTION; ADJUVANT CHEMOTHERAPY; ANIMAL; CATHETER ABLATION; HEAT; HYPERTHERMIC THERAPY; LIVER TUMOR; METHODOLOGY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; HOT TEMPERATURE; HUMANS; HYPERTHERMIA, INDUCED; LIPOSOMES; LIVER NEOPLASMS; LYSOPHOSPHATIDYLCHOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 65649146495     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560802677874     Document Type: Review

References (86)

1. Revised Global Burden of Disease (GBD) 2002; Estimates. World Health Organization. Available from: http://www.who.int/healthinfo/bodgbd2002;revised/ en/index.html [Last accessed 16 May 2008 ]
2. Johnson PJ, Williams R. Cirrhosis and the aetiology of hepatocellular carcinoma. J Hepatol 1987;4:140-147
3. Tang ZY, Curley SA. Liver cancer. 8th edition. In: Pollock RE, Doroshow JH, Khayat D, et al., editors. UICC Manual of Clinical Oncology, Hoboken, NJ: John Wiley & Sons, 2004. p. 405-427
4. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 1985;56:918-928
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-1917 (Pubitemid 37518510)
6. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42:1208-1236 (Pubitemid 43112690)
7. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649
8. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. J Clin Oncol 2005;23:2892-2899 (Pubitemid 46224106)
9. Bruix J, Sherman M, Llovet JM, et al. Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001;35:421-430 (Pubitemid 32844200)
10. Llovet JM, Di Bisceglie AM, Bruix M, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711
11. Uka K, Aikata H, Takaki S, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol 2007;13:414-420 (Pubitemid 46178976)
12. Yang Y, Nagano H, Ota H, et al. Patterns and clinicopathologic features of extrahepatic recurrence of hepatocellular carcinoma after curative resection. Surgery 2007;141:196-202 (Pubitemid 46149871)
13. Berber E, Herceg NL, Casto KJ, Siperstein AE. Laparoscopic radiofrequency ablation of hepatic tumors: prospective clinical evaluation of ablation size comparing two treatment algorithms. Surg Endosc 2004;18:390-396 (Pubitemid 38524504)
14. Berber E, Ari E, Herceg N, Siperstein A. Laparoscopic radiofrequency thermal ablation for unusual hepatic tumors: operative indications and outcomes. Surg Endosc 2005;19:1613-1617 (Pubitemid 41719530)
15. Berber E, Siperstein AE. Perioperative outcome after laparoscopic radiofrequency ablation of liver tumors: an analysis of 521 cases. Surg Endosc 2007;21:613-618 (Pubitemid 46439380)
16. Mulier S, Mulier P, Ni Y, et al. Complications of radiofrequency coagulation of liver tmours. Br J Surg 2002;89:1206-1222 (Pubitemid 36002536)
17. Galandi D, Antes G. Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma. Cochrane Database Syst Rev 2002;3:CD003046
18. Sutherland LM, Williams JA, Padbury RT, et al. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg 2006;141:181-190 (Pubitemid 43276571)
19. Garrean S, Hering J, Saied A, et al. Radiofrequency ablation of primary and metastatic liver tumors: a critical review of the literature. Am J Surg 2008;195:508-520
20. Lin SM, Lin CJ, Lin CC, et al. Randomized controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percuteanous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 2005;54:1151-1156 (Pubitemid 41025911)
21. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005;129:122-130 (Pubitemid 41002049)
22. Brunello F, Veltri A, Carucci P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008;43:727-735 (Pubitemid 351868714)
23. Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology 2004;127:1714-1723 (Pubitemid 39575850)
24. Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 2006;243:321-8 • Randomized trial showing that, for small/medium hepatocellular carcinoma, percutaneous radiofrequency ablation and surgical resection are not significantly different in overall survival; it also shows that percutaneous radiofrequency ablation is both less toxic and less costly than surgery. (Pubitemid 43327762)
25. Lencioni RA, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 2003;228:235-240 (Pubitemid 36736097)
26. Chen Q, Tong S, Dewhirst MW, Yuan F. Targeting tumor microvessels using doxorubicin encapsulated in a novel thermosensitive liposome. Mol Cancer Ther 2004;3:1311-1317 (Pubitemid 39440175)
27. Dodd GD 3rd, Frank Ms, Aribandi M, et al. Radiofrequency thermal ablation: computer analysis of the size of the thermal injury created by overlapping ablations. Am J Roentgenol 2001;177:777-782
28. Guglielmi A, Ruzzenente A, Battocchia A, et al. Radiofrequency ablation of hepatocellular carcinoma in cirrhotic patients. Hepatogastroenterology 2003;50:480-484 (Pubitemid 36390549)
29. Curley SA, Izzo F, Abdalla E, Vauthey JN. Surgical treatment of colorectal cancer metastasis. Cancer Metastasis Rev 2004;23:165-182 (Pubitemid 38221602)
30. Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005;103:1201-1209
31. Poon RT, Ng KK, Lam CM, et al. Effectiveness of radiofrequency ablation for hepatocellular carcinomas larger than 3 cm in diameter. Arch Surg 2004;139:281-287 (Pubitemid 38282669)
32. Vivarelli M, Guglielmi A, Ruzzenente A, et al. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg 2004;240:102-107 (Pubitemid 38808241)
33. Machi J, Bueno RS, Wong LL. Long-term follow-up outcome of patients undergoing radiofrequency ablation for unresectable hepatocellular carcinoma. World J Surg 2005;29:1364-1373 (Pubitemid 41712667)
34. Ng KK, Poon RT, Lo CM, et al. Analysis of recurrence pattern and its influence on survival outcome after radiofrequency ablation of hepatocellular carcinoma. J Gastrointest Surg 2008;12:183-191
35. Mulier S, Ni Y, Jamart J, et al. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 2005;242:158-171 (Pubitemid 41033431)
36. Chen MS, Zhang YJ, Li JQ, et al. Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency ablation alone for small hepatocellular carcinoma. Zhonghua Zhong Liu Za Zhi 2005;27:623-5 • Randomized trial showing that, for medium HCC, RFA alone is significantly less effective than RFA plus PEI.
37. Zhang YJ, Liang HH, Chen MS, et al. Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial. Radiology 2007;244:599-607 • Randomized trial showing that RFA plus PEI is significantly more effective than RFA alone for medium HCC but not for either small HCC or large HCC.
38. Doxorubicin Product Information, Bedford Laboratories, Bedford, OH, USA. Available from: http://www.bedfordlabs.com/products/inserts/ADR-P01.pdf [Last accessed 23 May 2008 ]
39. Product Monograph- Adriamycin: doxorubicin hydrochloride injection. Pfizer Canada Inc., Kirkland, Quebec, Canada, 2007. Available from: http://www.pfizer.ca/english/our%20products/prescription%20pharmaceuticals/ default.asp?s=1&id=35&doc=enmonograph [Last accessed 16 June 2008 ]
40. Nerenstone SR, Inde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev 1988;15:1-31 (Pubitemid 18137783)
41. Lai CL, Wu PC, Chan GC, et al. Doxorubicin vs. no antitumor therapy in an inoperable hepatocellular carcinoma: a prospective randomized trial. Cancer 1988;62:479-83 • Randomized trial showing that single-agent doxorubicin is superior to no anticancer treatment for HCC.
42. Yeo W, Mok TS, Zee B, et al. A randomized Phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005;97:1532-1538 (Pubitemid 41631953)
43. Gish RG, Porta C, Lazar L, et al. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007;25:3069-3075 (Pubitemid 47218053)
44. Ueoka H, Kuroda S, Ohnoshi T, et al. Intraarterial Adriamycin for patients with hepatocellular carcinoma and metastatic liver carcinoma. Gan To Kagaku Ryoho 1984;11:2579-2584 (Pubitemid 15192078)
45. Doci R, Bignami P, Bozzetti F, et al. Intrahepatic chemotherapy for unresectable hepatocellular carcinoma. Cancer 1988;61:1983-1987 (Pubitemid 18123478)
46. Kalayci C, Johnson PJ, Raby N, et al. Intraarterial adriamycin and lipiodol for inoperable hepatocellular carcinoma: a comparison with intravenous adriamycin. J Hepatol 1990;11:349-353
47. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, et al. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999;46:1122-1125 (Pubitemid 29224804)
48. Needham D, Ponce A. Nanoscale drug delivery vehicles for solid tumors: a new paradigm for localized drug delivery using temperature sensitive liposomes. In: Amiji M, editor. Nanotechnology in Cancer Therapy. Boca Raton, FL: CRC Press; 2006. p. 677-719
49. Bao A, Goins B, Klipper R, et al. Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther 2004;308:419-425 (Pubitemid 38134199)
50. Ahmed M, Monsky WE, Girnun G, et al. Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res 2003;63:6327-6333 (Pubitemid 37255180)
51. Ahmed M, Goldberg SN. Combination radiofrequency thermal ablation and adjuvant iv liposomal doxorubicin increases tissue coagulation and intratumoral drug accumulation. Int J Hyperthermia 2004;20:781-802 (Pubitemid 39496856)
52. Ahmed M, Lukyanov AN, Torchilin V, et al. Combined radiofrequency ablation and adjuvant liposomal chemotherapeutic: effect of chemotherapy agent, nanoparticle size, and circulation time. J Vasc Interv Radiol 2005;16:1365-1371 (Pubitemid 41463995)
53. Ahmed M, Liu Z, Lukyanov AN, et al. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology 2005;235:469-477 (Pubitemid 40571084)
54. Goldberg SN, Gazelle GS, Compton CC, et al. Treatment of intrahepatic malignancy with radiofrequency ablation: radiologic-pathologic correlation. Cancer 2000;88:2452-2463 (Pubitemid 30331950)
55. Goldberg SN, Kamel IR, Kruskal JB, et al. Radiofrequency ablation of hepatic tumors: increased tumor destruction with adjuvant liposomal doxorubicin therapy. Am J Roentgenol 2002;179:93-101 (Pubitemid 34694817)
56. Dvorak J, Zoul Z, Melichar B, et al. Liposomal doxorubicin combined with regional hyperthermia: reducing systemic toxicity and improving locoregional efficacy in the treatment of solid tumors. J Chemother 2004;16(Suppl 5):34-36 (Pubitemid 40052986)
57. Liu P, Xu LX, Zhang A. Enhanced efficacy of anti-tumor liposomal doxorubicin by hyperthermia. Conf Proc IEEE Eng Med Biol Soc 2006;1:4354-4357
58. ThermoDox®, Lyso-Thermosensitive Liposomal Doxorubicin: Investigator's Brochure for ThermoDox® in Combination with Focused Heat for the Treatment of Solid Tumors. Columbia, MD: Celsion Corporation, 2008 •• Presents LTLD chemistry, mechanism of action, pharmacokinetics, pharmacodynamics, and safety data.
59. Ng KK, Lam CM, Poon RT, et al. Thermal ablative therapy for malignant liver tumors: a critical appraisal. J Gastroenterol Hepatol 2003;18:616-629 (Pubitemid 36791698)
60. Herman TS, Sweets CC, White DM, Gerner EW. Effect of heating on lethality due to hyperthermia and selected chemotherapeutic drugs. J Natl Cancer Inst 1982;68:487-491
61. Herman TS. Temperature dependence of adriamycin, cis- diamminedichloroplatinum, bleomycin, and 1,3-bis(2-chloroethyl)-1-nitrosourea cytotoxicity in vitro. Cancer Res 1983;43:517-520 (Pubitemid 13193840)
62. Bates DA, Mackillop WJ. Hyperthermia, adriamycin transport, and cytotoxicity in drug-sensitive and-resistant Chinese hamster ovary cells. Cancer Res 1986;46:5477-5481 (Pubitemid 17177930)
63. Nagaoka S, Kawasaki S, Sasaki K, Nakanishi T. Intracellular uptake, retention and cytotoxic effect of adriamycin combined with hyperthermia in vitro. Jpn J Cancer Res 1986;77:205-211 (Pubitemid 16138117)
64. Nitta M, Hisazumi H, Nakajima K. Combined cell killing effects of anticancer drugs and hyperthermia in vitro. Hinyokika Kiyo 1988;34:1525-1528 (Pubitemid 18242645)
65. Calabro A, Singletary SE, Tucker S, et al. In vitro thermo- chemosensitivity screening of spontaneous human tumors: significant potentiation for cisplatin but not adriamycin. Int J Cancer 1989;43:385-390
66. Yoshida M. Effect of adriamycin combined with 40 and 43 degrees C hyperthermia on cultured V79 cells and S-180 tumor and their uptake of the drug. Nippon Igaku Hoshasen Gakkai Zasshi 1991;51:1098-1104
67. Uchibayashi T, Lee SW, Hisazumi H, et al. Studies of combined treatment of radiofrequency hyperthermia with anticancer agents or irradiation for invasive bladder cancer. Hinyokika Kiyo 1993;39:1209-1213
68. Uchibayashi T, Lee SW, Kunimi K, et al. Studies of effects of anticancer agents in combination with/without hyperthermia on metastasized human bladder cancer cells in chick embryos using the polymerase chain reaction technique. Cancer Chemother Pharmacol 1994;35(Suppl): S84-7 (Pubitemid 24357249)
69. Urano M, Begley J, Reynolds R. Interaction between adriamycin cytotoxicity and hyperthermia: growth-phase-dependent thermal sensitization. Int J Hyperthermia 1994;10:817-826 (Pubitemid 24352989)
70. Hayashi S, Kano E, Tsuji K, et al. Modification of thermosensitivity and chemosensitivity induced by combined treatments with hyperthermia and adriamycin. Int J Mol Med 2001;8:417-422
71. Istomin YP, Zhavrid EA, Alexandrova EN, et al. Dose enhancement effect of anticancer drugs associated with increased temperature in vitro. Exp Oncol 2008;30:56-59
72. Hauck ML, Larue SM, Petros WP, et al. Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res 2006;12:4004-4010 (Pubitemid 44078087)
73. Poon R, Ng K, Yuen J, et al. Phase I study of ThermoDox (thermally sensitive liposomes containing doxorubicin) given prior to radiofrequency ablation for unresectable liver cancers [Abstract]. Mumbai, India: International Hepato-Pancreato-Biliary Association Conference, 2008
74. A Phase I dose escalation study of heat activated liposome delivery of doxorubicin and radiofrequency ablation of primary and metastatic tumors of the liver (Study 104-03-101). Celsion Corporation, Columbia, Maryland, USA, 2008 [Clinical Study Report] •• Source of phase I RFA/LTLD efficacy data analyzed in this paper; also contains safety data.
75. Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 2002;132:605-611 (Pubitemid 35247322)
76. Curley SA, Levin B, Rich TA. Liver and bile ducts. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE, editors. Clinical Oncology. New York: Churchill Livingstone, 1995
77. Mini E, Dombrowski J, Moroson BA, Bertino JR. Cytotoxic effects of hyperthermia, 5-fluorouracil and their combination on a human leukemia T-lymphoblast cell line, CCRF-CEM. Eur J Cancer Clin Oncol 1986;22:927-934 (Pubitemid 16035143)
78. Shiiki S, Fuchimoto S, Iwagaki H, et al. Comparative antitumor activity of 5-fluorouracil and its prodrugs in combination with hyperthermia in vitro. Acta Med Okayama 1991;45:339-345
79. Maehara Y, Sakaguchi Y, Takahashi I, et al. 5-Fluorouracil's cytotoxicity is enhanced both in vitro and in vivo by concomitant treatment with hyperthermia and dipyridamole. Cancer Chemother Pharmacol 1992;29:257-260
80. Hong RL, Tseng YL. A Phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2003;51:433-438 (Pubitemid 36649142)
81. Lind PA, Naucler G, Holm A, et al. Efficacy of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Acta Oncol 2007;46:230-233 (Pubitemid 46272613)
82. Dvorák J, Zoul Z, Melichar B, et al. Pegylated liposomal doxorubicin in combination with hyperthermia in the treatment of a case of advanced hepatocellular carcinoma. J Clin Gastroenterol 2002;34:96-98 (Pubitemid 34038490)
83. Phase III, randomized, double-blinded, dummy-controlled study of the efficacy and safety of ThermoDox® (thermally sensitive liposomal doxorubicin) in combination with radiofrequency ablation (RFA) compared to RFA-alone in the treatment of non-resectable hepatocellular carcinoma. Columbia, MD, USA: Celsion Corporation, 2007 [Protocol] •• Will provide definitive test of RFA/LTLD therapy for medium/large HCC.
84. International Clinical Trials Registry. World Health Organization. Available from: http://www.who.int/trialsearch/advsearch.aspx; Study ID# NCT00617981 [Last accessed 4 June 2008 ] •• Will provide definitive test of RFA/LTLD therapy for medium/large HCC.
85. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Ass 1958;53:457-481
86. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br J Cancer 1977;35:1-39